Literature DB >> 10950411

A randomized controlled study of the use of transscleral diode laser and cryotherapy in the management of rhegmatogenous retinal detachment.

D H Steel1, J West, W G Campbell.   

Abstract

PURPOSE: Cryotherapy, the most common modality used to create a chorioretinal adhesion during retinal reattachment surgery, is associated with the dispersion of viable pigment epithelial cells and breakdown of the blood-ocular barrier, which are thought to be causative in a number of postoperative events, including macular pucker, proliferative vitreoretinopathy (PVR), and cystoid macular edema. Transscleral diode laser has been used successfully to create a chorioretinal adhesion in retinal reattachment surgery (diopexy) and experimentally has been shown to cause less pigment dispersion and blood-ocular barrier breakdown than cryotherapy. The authors carried out a prospective randomized study to compare the results and complication rates of transscleral diopexy with those of cryopexy during surgery for rhegmatogenous retinal detachment (RRD).
METHODS: Data from 120 patients with recent onset RRD without significant PVR who were suitable for scleral buckling surgery and randomized to treatment using diode laser or cryotherapy were analyzed. The primary outcome measure was reattachment at 6 months with one operation. Secondary outcome measures were pain and swelling on the first postoperative day, cystoid macular edema as assessed angiographically at 6 weeks, and visual acuity, macular epiretinal membrane, and pigment migration under the fovea at 3 months.
RESULTS: There was no significant difference between the primary and secondary outcome measures between the two treatment groups, with a primary success rate of 83% in the diode group and 92% in the cryotherapy group. Pain and postoperative swelling on the first postoperative day were equivalent. Cystoid macular edema was angiographically present in 12% in the diode group and 14% in the cryotherapy group. Visual acuity of at least 20/40 was achieved in 54% of patients in both groups. The rate of PVR was 5% in the diode group and 3% in the cryotherapy group.
CONCLUSION: In this study of patients with uncomplicated RD without significant preoperative PVR, the experimentally shown benefits of transscleral diode laser did not result in significant improvement in the results of reattachment surgery compared with cryotherapy.

Entities:  

Mesh:

Year:  2000        PMID: 10950411     DOI: 10.1097/00006982-200007000-00005

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

Review 1.  [Scleral buckling surgery and pneumatic retinopexy. Techniques, indications and results].

Authors:  H Hoerauf; H Heimann; L Hansen; H Laqua
Journal:  Ophthalmologe       Date:  2008-01       Impact factor: 1.059

2.  The Role of Cryotherapy in Vitreous Concentrations of Topotecan Delivered by Episcleral Hydrogel Implant.

Authors:  Martina Kodetova; Radka Hobzova; Jakub Sirc; Jiri Uhlik; Katerina Dunovska; Karel Svojgr; Ana-Irina Cocarta; Andrea Felsoova; Ondrej Slanar; Martin Sima; Igor Kozak; Pavel Pochop
Journal:  Pharmaceutics       Date:  2022-04-20       Impact factor: 6.525

3.  Incidence and risk factors for cystoid macular edema following scleral buckling.

Authors:  T-T Lai; J-S Huang; P-T Yeh
Journal:  Eye (Lond)       Date:  2016-12-09       Impact factor: 3.775

Review 4.  Scleral buckling-a brief historical overview and current indications.

Authors:  Aijing Wang; Martin P Snead
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-11       Impact factor: 3.117

5.  The feasibility and efficacy of intraoperative laser retinopexy in scleral buckling surgery.

Authors:  Roshija Khanal Rijal; Deepesh Mourya
Journal:  Oman J Ophthalmol       Date:  2019 May-Aug

Review 6.  Scleral Buckling: A Review of Clinical Aspects and Current Concepts.

Authors:  Matteo Fallico; Pietro Alosi; Michele Reibaldi; Antonio Longo; Vincenza Bonfiglio; Teresio Avitabile; Andrea Russo
Journal:  J Clin Med       Date:  2022-01-09       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.